Welcome to our dedicated page for Mannkind news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind stock.
About MannKind Corporation (NASDAQ: MNKD)
MannKind Corporation is a leading biopharmaceutical company specializing in the development and commercialization of innovative inhaled therapeutic products. With a mission to address serious unmet medical needs, MannKind focuses on two primary therapeutic areas: endocrine diseases, such as diabetes, and orphan lung diseases, including pulmonary arterial hypertension, pulmonary fibrosis, and nontuberculous mycobacterial (NTM) lung disease.
Core Business Areas
MannKind’s business model revolves around leveraging its proprietary Technosphere® dry-powder technology to deliver drugs via inhalation. This unique platform allows for rapid and effective drug delivery to the deep lungs, providing both systemic and localized therapeutic effects. The company generates revenue through a combination of commercial product sales, royalty agreements, and strategic collaborations.
Product Portfolio
- Afrezza®: A rapid-acting inhaled insulin for adults with diabetes, offering a convenient alternative to injectable insulin. It is approved in the U.S., Brazil, and recently India, where it is marketed through a partnership with Cipla Ltd.
- Tyvaso DPI®: MannKind manufactures this inhaled therapy for pulmonary arterial hypertension under a collaboration with United Therapeutics, contributing significantly to its royalty revenue.
- MNKD-101 (Clofazimine Inhalation Suspension): Currently in Phase 3 trials, this investigational therapy targets refractory NTM lung disease.
- MNKD-201 (Nintedanib DPI): An inhaled therapy for idiopathic pulmonary fibrosis, designed to reduce systemic side effects associated with oral formulations.
Proprietary Technologies
MannKind’s groundbreaking Technosphere® platform enables the creation of dry-powder formulations for inhalation, providing deep lung penetration and rapid onset of action. This technology is complemented by its proprietary inhalation devices, such as the Cricket® inhaler, which enhance patient convenience and adherence.
Market Segments and Competitive Positioning
MannKind operates in highly specialized markets, addressing both chronic and rare diseases. Its focus on inhaled therapies differentiates it from competitors offering traditional oral or injectable treatments. The company’s products cater to diverse patient populations, from adults with diabetes to individuals suffering from rare pulmonary conditions. Strategic partnerships, such as its collaboration with Cipla in India and licensing agreements with Pulmatrix, further strengthen its market presence.
Strategic Initiatives and Clinical Achievements
MannKind is actively advancing its clinical pipeline, with notable milestones including:
- Positive results from the Phase 4 INHALE-3 study, demonstrating the efficacy of Afrezza in improving glycemic control in type 1 diabetes.
- Phase 3 trials for MNKD-101 targeting NTM lung disease, with regulatory clearances in multiple countries.
- Completion of Phase 1 trials for MNKD-201, showing promise as a safer alternative for pulmonary fibrosis treatment.
Commitment to Innovation
With a passionate team and a robust pipeline, MannKind remains committed to revolutionizing drug delivery and improving patient outcomes. Its focus on inhaled therapeutics not only addresses unmet medical needs but also enhances the quality of life for patients worldwide.
MannKind (MNKD) reported strong financial results for Q4 and full year 2024. The company achieved annual revenues of $286M, up 43% from 2023, with Q4 revenues of $77M (+31% YoY). Net income for 2024 reached $28M, with Q4 contributing $7M.
Key financial highlights include debt principal reduction of $236M, with remaining convertible debt of $36M, and year-end cash position of $203M. The company made significant clinical progress, including positive results from the INHALE-1 pediatric trial for Afrezza, advancement of MNKD-101 to Global Phase 3, and completion of MNKD-201 Phase 1.
Commercial developments include Afrezza's approval in India with expected shipments in Q4 2025, and the appointment of Dominic Marasco as President of the Endocrine Business Unit. The company maintains a strong growth trajectory with an annual run rate of $300M by year-end.
MannKind (MNKD) has announced it will release its 2024 fourth quarter and full year financial results after market close on Wednesday, February 26, 2025. The company will host a webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update.
The conference call will feature CEO Michael Castagna and CFO Chris Prentiss. Investors can access the webcast through MannKind's website, and a replay will be available for approximately 90 days following the call.
MannKind (Nasdaq: MNKD), specializing in inhaled therapeutic products for endocrine and orphan lung diseases, has announced its participation in three major investor conferences during Q1 2025. The company's leadership, including CEO Michael Castagna and CFO Chris Prentiss, will present at:
- Oppenheimer 35th Annual Healthcare Life Sciences Conference (virtual) - February 11, 11:20 a.m. ET
- Leerink Partners 2025 Global Healthcare Conference in Miami - March 11, 8:40 a.m. ET
- Barclays 27th Annual Global Healthcare Conference in Miami - March 12, 1:30 p.m. ET
Live audio webcasts will be accessible through MannKind's investor relations website, with recordings available for approximately 90 days post-conference.
MannKind (MNKD) has appointed Dominic Marasco, RPh, as President of its Endocrine Business Unit, effective January 6, 2025. Marasco, who brings over 25 years of experience in biopharma and biotech sectors, will report to CEO Michael Castagna.
Marasco's most recent role was Executive President and Chief Commercial Officer at Envision Pharma Group, where he led technology and AI business units. His prior experience includes leadership positions at BioAgilytix Labs, Syneos Health, Amgen, Sandoz Biopharmaceuticals, and Eli Lilly. He holds a degree from the Philadelphia College of Pharmacy and completed Harvard Business School's Advanced Management Program.
The appointment aims to leverage Marasco's global experience to build upon Afrezza's positive clinical trial results and drive strategic growth in the company's endocrine business.
MannKind (MNKD) has announced significant debt restructuring through exchange agreements with certain holders of its 2.50% Convertible Senior Notes due 2026. The company will exchange approximately $193.7 million of Notes for 26,749,559 shares of common stock and make a cash payment of $89.2 million to the holders.
This transaction reduces MannKind's total outstanding debt by 84%, decreasing from $230 million to approximately $36.3 million. The exchange will save approximately 10.4 million shares of potential dilution and reduce annual interest expense by $4.9 million to $0.9 million. Following the exchange, MannKind's cash balance will exceed $180 million with approximately 302.5 million shares outstanding.
MannKind (MNKD) announced six-month results from its Phase 3 INHALE-1 study of Afrezza (inhaled insulin) in children and adolescents aged 4-17 years. The 26-week trial involved 230 subjects randomized to either Afrezza or multiple daily injections (MDI) of rapid-acting insulin.
The modified intent-to-treat (mITT) analysis, excluding one non-adherent patient, demonstrated non-inferiority of Afrezza to MDI with a between-group difference of 0.370% in HbA1c change, meeting the primary endpoint's threshold of 0.4%. No significant differences in lung function or safety parameters were observed between groups. The company plans to meet with FDA regarding a potential supplemental new drug application (sNDA) submission in first half of 2025.
MannKind (MNKD) announced that India's Central Drugs Standard Control Organisation (CDSCO) has approved Afrezza (insulin human) Inhalation Powder for adults. This approval follows existing approvals in the United States and Brazil. The company expects to ship the product to their partner Cipla by the end of 2025.
This milestone is particularly significant as India has the second-highest burden of diabetes worldwide, with over 74 million people affected. The partnership between MannKind and Cipla, established in May 2018, involves Cipla handling regulatory approvals, marketing, and sales in India, while MannKind is responsible for product supply.
According to the International Diabetes Federation, diabetes affects 537 million adults globally, with projections reaching 643 million by 2030 and 783 million by 2045.
MannKind (MNKD) reported strong financial results for Q3 2024, with total revenues reaching $70 million, up 37% from Q3 2023. Year-to-date revenues reached $209 million, a 49% increase from the previous year. The growth was primarily driven by Tyvaso DPI revenues, with royalties increasing 34% to $27.1 million. Afrezza net revenue grew 12% to $15 million. The company achieved a net income of $20 million year-to-date and reported significant progress in clinical trials, including MNKD-101 Phase 3 expansion and successful completion of MNKD-201 Phase 1.
MannKind (Nasdaq: MNKD) has announced its participation in the 2024 UBS Healthcare Conference in Rancho Palos Verdes, California. CEO Michael Castagna and CFO Chris Prentiss will participate in a fireside chat on Tuesday, November 12, at 10:15 a.m. Pacific Time. The company, which specializes in developing inhaled therapeutic products for endocrine and orphan lung diseases, will provide company updates during the session. The presentation will be accessible via live audio webcast on MannKind's website, with a recorded version available for approximately 30 days after the event.
MannKind (MNKD) announced successful completion of Phase 1 trial for nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases. The trial met its primary objective, demonstrating safety and tolerability in healthy volunteers. Key highlights include absence of typical adverse events associated with oral nintedanib, particularly GI and neurologic events. Only mild, transient adverse events were noted - cough and FEV-1 drop, which fully recovered. The study included single and multiple-ascending doses in adults over 40 years. The company plans to meet with FDA in first half of 2025 to discuss late-stage development.
FAQ
What is the current stock price of Mannkind (MNKD)?
What is the market cap of Mannkind (MNKD)?
What does MannKind Corporation specialize in?
What is Afrezza?
What is the Technosphere® platform?
What are MannKind's key therapeutic areas?
How does MannKind generate revenue?
What is MNKD-101?
Who are MannKind's key partners?
What makes MannKind's inhaled therapies unique?
